• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics (NQ: SRPT )

    122.33 -2.56 (-2.05%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 723,072
    Open 125.00
    Bid (Size) 122.39 (1)
    Ask (Size) 125.00 (40)
    Prev. Close 124.89
    Today's Range 121.66 - 125.73
    52wk Range 55.25 - 173.25
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
    Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
    Via MarketBeat
    Exposures Product Safety

    Performance

    YTD
    +27.15%
    +27.15%
    1 Month
    -9.45%
    -9.45%
    3 Month
    -21.96%
    -21.96%
    6 Month
    -4.73%
    -4.73%
    1 Year
    +3.15%
    +3.15%

    More News

    Read More
    Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Unveiling 26 Analyst Insights On Sarepta Therapeutics
    Via Benzinga
    How Is The Market Feeling About Sarepta Therapeutics?
    Via Benzinga
    Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    These 2 Biotech Stocks Are Set to Soar
    Via The Motley Fool
    Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
    Via Benzinga
    A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
    Via Benzinga
    $100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
    Via Benzinga
    Smart Money Is Betting Big In SRPT Options
    Via Benzinga
    Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
    Via Investor's Business Daily
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
    Via MarketBeat
    2 Biotech Stocks to Buy Hand Over Fist in August
    Via The Motley Fool
    Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
    Via Benzinga
    How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
    Via Investor's Business Daily
    McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    7 Biotech Stocks to Buy for Their Game-Changing Potential
    Via InvestorPlace
    Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.